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Introduction: Acetylcarnitine (ALCAR) is known to facilitate the influx and efflux of acetylgroups across the mitochondrial membrane and buffers 
an excess in acetylCoA in both cytosolic and mitochondrial compartments [1]. Acetylcarnitine is a necessary intermediate for mitochondrial acetate 
metabolism [2] and has been shown to easily cross the blood brain barrier and act as a neuroprotective agent [3] and used for Alzheimer’s disease 
treatment in humans [4]. The advent of hyperpolarized MR allows for study of real-time metabolism and offers the possibility to determine the 
kinetics of specific biochemical transformations in vivo [5]. The conversion of hyperpolarized acetate into acetylcarnitine, acetylCoA [6] and citrate 
[7] has been probed in vivo in cardiac muscle and reflect several enzymatic activities.  These downstream metabolites appear with a time delay and 
typically decay corresponding to their T1. The aim of the present study was to explore the use of hyperpolarized acetylcarnitine as a tracer since it 
easily enters the mitochondrion and skips two cytosolic biochemical transformations needed for acetate to enter the mitochondrion. Secondly, the use 
of hyperpolarized acetylcarnitine could help elucidate the backflux through the reaction from acetylcarnitine to acetylCoA to describe the entire 
system of enzymatic reactions in more detail.  
 
Materials and methods: Acetyl-1-13C-L-carnitine hydrochloride (1.5M) solved in a 1:2 mixture of d6-EtOD/D2O containing 33mM TEMPO free 
radical were turned into frozen glassy beads and subsequently polarized in a custom-designed 5T DNP polarizer for 2 h [8]. After dissolution, the 
samples were transferred within 2 s into a home-built infusion pump located inside the magnet bore (9.4T) and connected to a catheter inserted into a 
D2O filled phantom or the rat femoral vein (n=3). The 5 s long infusion of 1 mL hyperpolarized ALCAR solution was triggered 1 s later. The whole 
procedure was computer controlled in order to obtain an identical timing for all experiments. At the end of the in vivo acquisition, the residual 
solution in the infusion pump was extracted and measured in a high-resolution 400 MHz spectrometer (Bruker) to determine the acetate 
concentration. Series of single pulse acquisitions were recorded using 10° (in vitro) or 30° (in vivo) adiabatic RF pulses applied every 1 or 3 s starting 
at the end of the infusion with a homebuilt surface coil with 13C in quadrature mode. The in vivo acquisitions were respiratory gated and cardiac 
triggered. Spectra were analysed in jMRUI and Matlab.  
 
Results and discussion: The T1 of [1-13C]acetylcarnitine was found to be 15 s in blood at physiological temperature and around 16 s in D2O (table 1). 
[1-13C]acetylcarnitine was dynamically polarized with a buildup constant of 1390 s. After dissolution in a D2O loaded phantom and data acquisition, 
the hyperpolarized time integrals were corrected for repeated adiabatic 10° excitations and the decay constant as a result of T1 was 14.7 ± 1.0 s. In 
vivo experiments: A volume of 1 mL 100 mM [1-13C]acetylcarnitine was infused in healthy rats and the time evolution of substrate and two 
metabolic products (figure 1) were measured in 3 animals. The linewidth of acetylcarnitine observed at 173.9 ppm was between 25 and 30 Hz. As 
expected given the relative short relaxation time the acetylcarnitine signal could be observed during 20 to 40 seconds exhibiting a mono-exponential 
decay of around 3 s regardless of the TR.  The resonance of [5-13C]glutamate appeared at 182.4 ppm, which cannot be observed using hyperpolarized 
acetate as a tracer because their resonances overlap (182.6 ppm vs. 182.4 ppm). Surprisingly [5-13C]citrate, resonating at 179.7 ppm was not observed 
in these experiments but another, yet unknown metabolite resonance was observed at 177.7 ppm. High res NMR on the infused solution did not 
reveal any impurities. We have not been able to assign this resonance but a possible candidates are [5-13C]glutamine or glutathione.  
 
Conclusion: Despite its short T1 it was possible to detect the formation of glutamate from hyperpolarized [1-13C]ALCAR. An additional metabolite 
was detected which does not correspond to cardiac metabolites observed following a hyperpolarized [1-13C]acetate injection. This study highlights 
the intricate relationship between reaction, transport and relaxation rates in the choice of hyperpolarized substrates.  
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Fig. 1: In vivo cardiac 13C NMR spectrum at t = 6 s following
the infusion of hyperpolarized [1-13C]ALCAR. [5-
13C]glutamate is observed at 182.4 ppm and another
resonance at 177.7 ppm. The right panel shows a integrated
spectral time course of an experiment with TR = 1 s  
 
Solvent T1 in [s] 
Plasma  
T = 310 K 
14.9 ± 0.7 
D
2
O T = 295 K 10.3 ± 0.8   
D
2
O T = 305 K 14.3 ± 0.5 
D
2
O T = 310 K 15.5 ± 0.5  
 
Table 1. Longitudinal relaxation 
times of [1-13C]ALCAR in D2O 
and  plasma.   
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